|
|
Volumn 28, Issue 5, 2010, Pages 387-389
|
|
Abbott outbids Biogen for Facet's multiple sclerosis antibody
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
ANTINEOPLASTIC AGENT;
BETA1A INTERFERON;
CLADRIBINE;
DACLIZUMAB;
ELOTUZUMAB;
FINGOLIMOD;
GLATIRAMER;
INTERFERON BETA SERINE;
NATALIZUMAB;
PDL 192;
PDL 241;
UNCLASSIFIED DRUG;
VOLOCIXIMAB;
CLINICAL TRIAL;
DRUG COST;
DRUG MARKETING;
DRUG RESEARCH;
HUMAN;
MULTIPLE MYELOMA;
MULTIPLE SCLEROSIS;
NEOPLASM;
NOTE;
PRIORITY JOURNAL;
SOLID TUMOR;
ANTIBODIES, MONOCLONAL;
BIOTECHNOLOGY;
CLINICAL TRIALS AS TOPIC;
COMPETITIVE BIDDING;
DRUG INDUSTRY;
HUMANS;
IMMUNOGLOBULIN G;
MULTIPLE SCLEROSIS;
|
|
EID: 77952130995
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0510-387 Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|
